Combined modality treatments in pancreatic cancer. - Wikidata - awgldk - TriplyDB

Combined modality treatments in pancreatic cancer.

Combined modality treatments in pancreatic cancer.

http://www.wikidata.org/entity/Q37996462

about

Long-Circulating Curcumin-Loaded Liposome Formulations with High Incorporation Efficiency, Stability and Anticancer Activity towards Pancreatic Adenocarcinoma Cell Lines In Vitro Recombinant adenovirus-p53 (Gendicine) sensitizes a pancreatic carcinoma cell line to radiation.The Development of a Novel Therapeutic Strategy to Target Hyaluronan in the Extracellular Matrix of Pancreatic Ductal Adenocarcinoma.Optimize radiochemotherapy in pancreatic cancer: PARP inhibitors a new therapeutic opportunity

P2860

Q28554939-D07844F2-67A6-415E-A51D-68EDC572AC2F Q37413649-623770AF-2DAD-4177-9E83-6F835EBCB3D5 Q37729238-C356B8D8-85A3-49C4-A237-C2431E7C43C8 Q39245474-6AF4A66E-D98C-4D81-A684-AD5CF29A3A65

P2860

Combined modality treatments in pancreatic cancer.

http://www.wikidata.org/entity/Q37996462

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Combined modality treatments in pancreatic cancer.

@en

Combined modality treatments in pancreatic cancer.

@nl

type

label

Combined modality treatments in pancreatic cancer.

@en

Combined modality treatments in pancreatic cancer.

@nl

prefLabel

Combined modality treatments in pancreatic cancer.

@en

Combined modality treatments in pancreatic cancer.

@nl

P1433

Q37996462-3F7C6220-6D8B-42DF-A827-64883B730CEB

P1476

Q37996462-A1F956BD-C984-4D2E-88D7-1BB87CA80A4B

P2093

Q37996462-13C41EFD-038B-498F-939E-4DDE048B6D6A

Q37996462-29B13FA5-E945-4247-8080-7B1AC1FAE180

Q37996462-373C4D7D-0787-4006-BC14-5BDEB6FA35F4

Q37996462-553BE838-48B5-4F46-A1D3-2B368967DD1C

Q37996462-8B71B92C-CBEC-40F3-A3B7-12B045D92AF7

Q37996462-8CBB38FC-9160-45CC-9A91-64F48EB4A91E

Q37996462-99CB2D5D-F7DD-44DD-819A-0619D532E4C7

Q37996462-ACE4F85A-0667-4C74-9771-E9F23FA0CA2F

Q37996462-FBA49F33-6A6A-4C16-93C3-7DAD7F5A40E0

Q37996462-FF8EAAE0-4F1F-4EDA-AFA7-242949481264

P2860

Q37996462-0BD738CF-4A05-4F4A-85AC-C22055830D70

Q37996462-0FD8B9F9-FAA6-4331-B7DD-D6EAF863B46B

Q37996462-102134D2-E732-4C16-8ADA-46ABD9622D44

Q37996462-14588C12-B872-45B3-8C83-6A7A8092A789

Q37996462-24573D23-54F4-4F6F-8FCC-14A7DA9BCF8C

Q37996462-25A9F47C-ED7B-41C7-B646-302CB373B661

Q37996462-2EB82E1F-6C18-42B5-8FD8-630F83DE0C47

Q37996462-3474E7CE-C598-48DC-A309-D3046C5403D1

Q37996462-356A87D7-66F1-4D0A-984B-8D3A9A4285D9

Q37996462-3A676548-F200-44F0-8E98-AF85FD4A6B94

P304

Q37996462-B7D87378-0072-4913-AF29-7C68CF4E3B0D

P31

Q37996462-3AF37F45-87B1-4A63-9E7B-F713FA56E2FE

P356

Q37996462-2DE27AA0-F028-436E-BCF8-D564815C2490

P407

Q37996462-29D531F5-BABC-4889-B704-8E6295F75B93

P478

Q37996462-CB7887FC-880F-4330-9756-3A8D2E1B6A85

P577

Q37996462-E7F16CE9-D8A0-4177-9D8E-7C949BEECB5D

P698

Q37996462-C4C67EE5-C76E-4EC3-ADF5-C04E5BC58570

P356

14728222.2012.662959

P1433

Expert Opinion on Therapeutic Targets

P1476

Combined modality treatments in pancreatic cancer.

@en

P2093

Evaristo Maiello

http://www.w3.org/2001/XMLSchema#string

Gabriele Di Maggio

http://www.w3.org/2001/XMLSchema#string

Giuseppe Colucci

http://www.w3.org/2001/XMLSchema#string

Lucia Lombardi

http://www.w3.org/2001/XMLSchema#string

Luciano Nanni

http://www.w3.org/2001/XMLSchema#string

Michele Troiano

http://www.w3.org/2001/XMLSchema#string

Nicola Silvestris

http://www.w3.org/2001/XMLSchema#string

Pierluigi Di Sebastiano

http://www.w3.org/2001/XMLSchema#string

Saverio Cinieri

http://www.w3.org/2001/XMLSchema#string

Tiziana Pia Latiano

http://www.w3.org/2001/XMLSchema#string

P2860

Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages

An Italian study on treatment trends and outcomes of patients with stage III pancreatic adenocarcinoma in the gemcitabine era: is it time to change?

DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer.

Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer

Cancer statistics, 2005

Definitive results of a phase II trial of cisplatin, epirubicin, continuous-infusion fluorouracil, and gemcitabine in stage IV pancreatic adenocarcinoma.

Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial.

Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group.

Neoadjuvant therapy may lead to successful surgical resection and improved survival in patients with borderline resectable pancreatic cancer.

Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group.

P304

S71-81

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14728222.2012.662959

http://www.w3.org/2001/XMLSchema#string

P407

P478

16 Suppl 2

http://www.w3.org/2001/XMLSchema#string

P577

2012-03-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22443336

http://www.w3.org/2001/XMLSchema#string